Skip to main content

General Rheumatology

      I've always (very) simplistically considered post-CAR-T CRS and HLH/MAS in the same bucket, and there certainly are subs

      David Liew drdavidliew

      4 days 23 hours ago
      I've always (very) simplistically considered post-CAR-T CRS and HLH/MAS in the same bucket, and there certainly are substantial similarities. It raises the obvious question - can we borrow therapies? @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/2HkHxpl89u
      What dictates how severe CRS is following CAR-T?
      (Often the critical question, and will especially be in the autoimmune

      David Liew drdavidliew

      4 days 23 hours ago
      What dictates how severe CRS is following CAR-T? (Often the critical question, and will especially be in the autoimmune space, where CAR-T is largely less time-critical) @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/u0w4lx7YVn
      @CarolineDiorio @ChildrensPhila eloquently told the #ACR25 BCRC pre-meeting about the lessons they've learned about CRS

      David Liew drdavidliew

      4 days 23 hours ago
      @CarolineDiorio @ChildrensPhila eloquently told the #ACR25 BCRC pre-meeting about the lessons they've learned about CRS and ICANS, the major CAR-T toxicities. Many questions still to answer, but they've also understood a lot we can learn from. @RheumNow https://t.co/Jhk1eCLpD4
      CAR-T toxicity in hematology
      (the things we have to look out for in rheumatology, as application of CAR-T potentially br

      David Liew drdavidliew

      4 days 23 hours ago
      CAR-T toxicity in hematology (the things we have to look out for in rheumatology, as application of CAR-T potentially broadens) @andrew02114 @MGHCancerCenter with the heme-onc point of view in the #ACR25 BCRC @RheumNow https://t.co/1YjadL7LCF
      Andrew Yee @andrew02114 of @MGHCancerCenter details out how quickly the CAR-T paradigm changed in myeloma/lymphoma - fro

      David Liew drdavidliew

      4 days 23 hours ago

      Andrew Yee @andrew02114 of @MGHCancerCenter details out how quickly the CAR-T paradigm changed in myeloma/lymphoma - from newsworthy to routine. Now that much more about CAR-T has been worked out, will adoption be quicker in autoimmune disease? #ACR25 BCRC pre-meeting @RheumNow https://t.co/oNuPXCwWQ9

      Post-CAR-T myelopathy has been an issue in heme onc, and is still an unpredictable quantity without a clear cause. Will

      David Liew drdavidliew

      5 days ago

      Post-CAR-T myelopathy has been an issue in heme onc, and is still an unpredictable quantity without a clear cause. Will this be a problem for autoimmune CAR-T as we gain more experience? @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/RhhdOiyEAX

      In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespira

      Antoni Chan MD (Prof) synovialjoints

      5 days 19 hours ago
      In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespiratory fitness ( increased oxygen pulse, ventilatory efficiency, anaerobic threshold). BASDAI and chest expansion also improved. Supports tailored rehab based on https://t.co/jawosa2AJK
      Abstract 2690: Food as a Medicine
      Mediterranean vs low-calorie DASH vs control diet in PsA (multicenter RCT):
      🔹 All

      Akhil Sood MD, MS AkhilSoodMD

      5 days 19 hours ago
      Abstract 2690: Food as a Medicine Mediterranean vs low-calorie DASH vs control diet in PsA (multicenter RCT): 🔹 All 3 groups showed significant weight loss & DAPSA by wk 24 🔹 Weight loss not diet type may be the driver of clinical improvement @RheumNow #ACR25 https://t.co/rBS3HR1HXl
      Abstract 2696: Phase 1/2 study of rapidly engineered CD19 CAR T showed:
      - rapid depletion of CD19 B cells w/ recovery by

      Akhil Sood MD, MS AkhilSoodMD

      5 days 20 hours ago
      Abstract 2696: Phase 1/2 study of rapidly engineered CD19 CAR T showed: - rapid depletion of CD19 B cells w/ recovery by Day 90 - Days 180 and 360: returning B cells largely naive (CD27-IgD+) - Interferon expression ↓ after CAR T treatment @RheumNow #ACR25 https://t.co/FzdFbqWwtE
      #ACR25 Clinical Preview by Prof Coates to be applied tomorrow!

      GC #steroid burden & Mx

      Abstr#738 Survey of #GCA p

      Md Yuzaiful Md Yusof Yuz6Yusof

      5 days 21 hours ago
      #ACR25 Clinical Preview by Prof Coates to be applied tomorrow! GC #steroid burden & Mx Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic @RheumNow https://t.co/paw7NGjs4p
      Does diet matter in PsA?

      Randomized study comparing advice, DASH low calorie, Mediterranean diet

      Seems that weight los

      David Liew drdavidliew

      5 days 21 hours ago
      Does diet matter in PsA? Randomized study comparing advice, DASH low calorie, Mediterranean diet Seems that weight loss corresponds better with benefit than diet. BMI reduction remains focus in PsA Laura Coates #ACR25 meeting review @RheumNow https://t.co/CqR25sJdDc
      ×